CIBC Asset Management Inc Buys New Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

CIBC Asset Management Inc acquired a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 1,875 shares of the specialty pharmaceutical company’s stock, valued at approximately $209,000.

A number of other hedge funds and other institutional investors have also modified their holdings of JAZZ. LSV Asset Management raised its stake in Jazz Pharmaceuticals by 4.2% in the second quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company’s stock valued at $264,750,000 after buying an additional 99,705 shares in the last quarter. Pacer Advisors Inc. lifted its stake in Jazz Pharmaceuticals by 40.7% during the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock worth $194,346,000 after purchasing an additional 527,187 shares during the last quarter. Baupost Group LLC MA boosted its holdings in Jazz Pharmaceuticals by 52.8% in the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock valued at $136,000,000 after purchasing an additional 440,552 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Jazz Pharmaceuticals by 48.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,222,198 shares of the specialty pharmaceutical company’s stock valued at $130,447,000 after purchasing an additional 398,549 shares during the last quarter. Finally, Swedbank AB acquired a new stake in Jazz Pharmaceuticals during the second quarter worth approximately $106,936,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Piper Sandler restated an “overweight” rating and issued a $163.00 target price (down previously from $166.00) on shares of Jazz Pharmaceuticals in a report on Thursday. Wells Fargo & Company dropped their price objective on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 1st. Needham & Company LLC reiterated a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Finally, JPMorgan Chase & Co. raised their price objective on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $175.33.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the transaction, the executive vice president now owns 33,048 shares in the company, valued at $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. The trade was a 8.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,110 shares of company stock worth $720,160 over the last ninety days. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Stock Up 1.3 %

Shares of NASDAQ:JAZZ opened at $126.67 on Friday. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.17. The stock has a 50-day simple moving average of $113.29 and a 200-day simple moving average of $110.62. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock has a market capitalization of $7.66 billion, a P/E ratio of 17.62, a PEG ratio of 0.98 and a beta of 0.57.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.